首页> 外文OA文献 >Radiofrequency ablation as locoregional therapy for unresectable hepatic malignancies: initial results in 24 patients with 5-years follow-up
【2h】

Radiofrequency ablation as locoregional therapy for unresectable hepatic malignancies: initial results in 24 patients with 5-years follow-up

机译:射频消融治疗不能切除的肝脏恶性肿瘤的局部治疗:24例随访5年的初步结果

摘要

Radiofrequency ablation (RFA) is one treatment modality for unresectable liver metastases. Patients with hepatic malignancies (n = 24) underwent elective RFA. All tumors were ablated with a curative intent, with a margin of 1 cm, in a single session of RFA. The median diameter of tumor was 3.1 cm (range 1.7-6.9 cm). Studied patients were not candidates for resection due to multifocal hepatic disease, extrahepatic disease, proximity to major vascular structures or presence of cirrhosis with functional hepatic reserve inadequate to tolerate major hepatic resection. Complete tumor necrosis was achieved in 87.5% and tumor recurred in 3 patients (12.5%) with lesions larger than 5 cm. Distant intrahepatic recurrence was diagnosed in another 4 (16.7%). Distant metastases were found in 7 (29.2%) patients. Four of these 7 patients had also distant intrahepatic recurrence of disease. Two and 5-years survival rates were 41.7% (10 patients) and 8.3% (2 patients) respectively. RFA is safe and effective option for patients with unresectable hepatic malignancies smaller than 5 cm without distant metastatic disease. RF ablation resulted in complete tumor necrosis in 87.5% with 2 and 5-years survival rates much higher than with chemotherapy alone or only supportive therapy, when survival is measured in weeks or months. If RFA is unavailable, percutaneous ethanol injection therapy can be done but with inferior survival rates.
机译:射频消融(RFA)是不可切除的肝转移的一种治疗方式。肝恶性肿瘤(n = 24)患者接受选择性RFA。在一次RFA疗程中,所有根治性肿瘤均已根治,切缘为1 cm。肿瘤的中值直径为3.1厘米(范围1.7-6.9厘米)。由于多灶性肝病,肝外疾病,邻近主要血管结构或存在功能性肝储备不足而不能耐受大范围肝切除的肝硬化患者,被研究的患者不适合切除。完全的肿瘤坏死率为87.5%,3例(12.5%)大于5厘米的病灶复发。另有4例(16.7%)被诊断为肝内远处复发。 7例(29.2%)患者发现远处转移。这7名患者中有4名也有远处肝内疾病复发。两年和五年生存率分别为41.7%(10例患者)和8.3%(2例患者)。对于无法切除的小于5 cm且无远处转移性疾病的肝恶性肿瘤,RFA是安全有效的选择。当在几周或几个月内测量生存率时,射频消融可导致87.5%的肿瘤完全坏死,且2年和5年生存率远高于单纯化疗或仅采用支持疗法。如果无法使用RFA,可以进行经皮乙醇注射疗法,但生存率较低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号